Exploring Analyst Estimates for Edwards Lifesciences (EW) Q3 Earnings, Beyond Revenue and EPS

The upcoming report from Edwards Lifesciences (EW) is expected to reveal quarterly earnings of $0.59 per share, indicating a decline of 11.9% compared to the year-ago period. Analysts forecast revenues of $1.5 billion, representing an increase of 11.1% year over year.The consensus EPS estimate for the quarter has been revised 0.9% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.Bearing this in mind, let's now explore the average estimates of specific Edwards Lifesciences metrics that are commonly monitored and projected by Wall Street analysts.The collective assessment of analysts points to an estimated 'Net Sales by Product Group- Transcatheter Mitral and Tricuspid Therapies' of $141.97 million. The estimate points to a change of +55.8% from the year-ago quarter.Analysts expect 'Net Sales by Product Group- Surgical Structural Heart' to come in at $255.09 million. The estimate indicates a change of +6.3% from the prior-year quarter.The consensus among analysts is that 'Net Sales by Product Group- Transcatheter Aortic Valve Replacement' will reach $1.11 billion. The estimate indicates a year-over-year change of +8%.Analysts' assessment points toward 'Net Sales- Europe' reaching $350.29 million. The estimate suggests a change of +9.5% year over year.The combined assessment of analysts suggests that 'Net Sales- Outside of the United States' will likely reach $636.85 million. The estimate indicates a change of +15.8% from the prior-year quarter.According to the collective judgment of analysts, 'Net Sales- United States' should come in at $862.73 million. The estimate suggests a change of +7.2% year over year.Analysts predict that the 'Net Sales- Japan' will reach $87.30 million. The estimate indicates a change of +7.3% from the prior-year quarter.It is projected by analysts that the 'Net Sales- Rest of World' will reach $199.26 million. The estimate suggests a change of +34.1% year over year. View all Key Company Metrics for Edwards Lifesciences here>>> Shares of Edwards Lifesciences have experienced a change of +4.7% in the past month compared to the +3.6% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), EW is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .Quantum Computing Stocks Set To SoarArtificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.Access the Report Free Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Edwards Lifesciences Corporation (EW): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks